Ewha Med J.  2017 Jan;40(1):22-28. 10.12771/emj.2017.40.1.22.

Gut Microbiota in Health and Probiotics in Functional Bowel Disease

• Rhyou JH

• KMID: 2367893
• DOI: http://doi.org/10.12771/emj.2017.40.1.22

Abstract

Microorganisms coexist in the human body and its function is essential to maintain normal physiology and homeostasis. Microbiota refers to the entire population of microorganisms that colonizes a particular location; includes not just bacteria but also other microbes. Gut microbiota is vast and complex. It could be changed dynamically according to the variable factors. Well balanced host-microbial symbiotic state is a harmonious ecosystem in the stable individual. But, dysbiosis is a state of deviation in composition or function from the usual gut microbiota. It has been found that this condition is associated with many gastrointestinal, metabolic, allergic and the other diseases. Dysbiosis plays an important role in the pathophysiology of functional bowel disease, such as irritable bowel syndrome and functional constipation. Probiotics is microorganism which, when administrated in adequate amounts, confer a health benefit on the host. Probiotics have beneficial effects to reduce several symptoms of functional bowel diseases. Currently, complementary and alternative medicine therapies with probiotics is recommended for symptomatic relief from functional bowel disease.

Keyword

Gastrointestinal microbiome; Dysbiosis; Probiotics; Functional bowel disease; Irritable bowel syndrome

MeSH Terms

Bacteria
Colon
Complementary Therapies
Constipation
Dysbiosis
Ecosystem
Gastrointestinal Microbiome*
Homeostasis
Human Body
Insurance Benefits
Irritable Bowel Syndrome
Microbiota
Physiology
Probiotics*

Reference

1. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015; 21:8787–8803.

2. Kim BS, Jeon YS, Chun J. Current status and future promise of the human microbiome. Pediatr Gastroenterol Hepatol Nutr. 2013; 16:71–79.

3. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011; 17:252–266.

4. Theodorou V, Ait Belgnaoui A, Agostini S, Eutamene H. Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes. 2014; 5:430–436.

5. Iovino P, Bucci C, Tremolaterra F, Santonicola A, Chiarioni G. Bloating and functional gastro-intestinal disorders: where are we and where are we going? World J Gastroenterol. 2014; 20:14407–14419.

6. Lee KJ. Treatment of irritable bowel syndrome. Korean J Med. 2011; 80:499–504.

7. Kim JM. Roles of enteric microbial composition and metabolism in health and diseases. Korean J Gastroenterol. 2013; 62:191–205.

8. Clauson ER, Crawford P. What you must know before you recommend a probiotic. J Fam Pract. 2015; 64:151–155.

9. de Moreno de LeBlanc A, LeBlanc JG. Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J Gastroenterol. 2014; 20:16518–16528.

10. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol. 2014; 20:2470–2481.

11. Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014; 20:15163–15176.

12. Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, et al. Change of fecal flora and effectiveness of the short-term VSL#3 probiotic treatment in patients with functional constipation. J Neurogastroenterol Motil. 2015; 21:111–120.

13. Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015; 9:318–331.

14. Kim JW. What is the therapeutic mechanism of the probiotics in irritable bowel syndrome patients with visceral hypersensitivity? J Neurogastroenterol Motil. 2014; 20:555–557.

15. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology. 2014; 146:1500–1512.

16. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol. 2014; 20:8886–8897.

17. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014; 39:1033–1042.

18. Park MI. Diagnosis and treatment of functional bloating. Korean J Med. 2012; 83:562–567.

19. Kvasnovsky CL, Bjarnason I, Papagrigoriadis S. What colorectal surgeons should know about probiotics: a review. Colorectal Dis. 2015; 17:840–848.

20. Bull MJ, Plummer NT. Part 1: the human gut microbiome in health and disease. Integr Med (Encinitas). 2014; 13:17–22.

21. Dore J, Simren M, Buttle L, Guarner F. Hot topics in gut microbiota. United European Gastroenterol J. 2013; 1:311–318.

22. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol. 2013; 19:5973–5980.

23. Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc. 2016; 49:257–265.

24. Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli MV, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015; 8:309–325.

25. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015; 54:243–249.

26. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol. 2014; 20:14105–14125.

27. Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011; 5:253–266.

28. Oshima T, Miwa H. Epidemiology of functional gastrointestinal disorders in Japan and in the world. J Neurogastroenterol Motil. 2015; 21:320–329.

29. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014; 109:1547–1561.

30. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014; 20:8796–8806.

31. Kwon JG, Park KS, Park JH, Park JM, Park CH, Lee KJ, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol. 2011; 57:82–99.

32. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol. 2014; 20:2456–2469.

33. Moloney RD, O'Mahony SM, Dinan TG, Cryan JF. Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry. 2015; 6:15.

34. Floch MH. Recommendations for probiotic use in humans: a 2014 update. Pharmaceuticals (Basel). 2014; 7:999–1007.

35. Mazurak N, Broelz E, Storr M, Enck P. Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about it? J Neurogastroenterol Motil. 2015; 21:471–485.

36. Hur KY, Lee MS. Gut microbiota and metabolic disorders. Diabetes Metab J. 2015; 39:198–203.

37. Martinez RC, Bedani R, Saad SM. Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br J Nutr. 2015; 114:1993–2015.

38. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, et al. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver. 2009; 3:101–107.

39. Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014; 100:1075–1084.

40. Ojetti V, Ianiro G, Tortora A, D'Angelo G, Di Rienzo TA, Bibbo S, et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis. 2014; 23:387–391.

41. Choi CH, Chang SK. Alteration of gut microbiota and efficacy of probiotics in functional constipation. J Neurogastroenterol Motil. 2015; 21:4–7.

42. Heo J, Kim SK, Park KS, Jung HK, Kwon JG, Jang BI. A double-blind, randomized, active drug comparative, parallel-group, multi-center clinical study to evaluate the safety and efficacy of probiotics (Bacillus licheniformis, Zhengchangsheng® capsule) in patients with diarrhea. Intest Res. 2014; 12:236–244.

43. Lee KJ. Pharmacologic Agents for Chronic Diarrhea. Intest Res. 2015; 13:306–312.

44. Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015; 57:129–134.

45. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015; 21:3072–3084.

46. Santos AR, Whorwell PJ. Irritable bowel syndrome: the problem and the problem of treating it. Is there a role for probiotics? Proc Nutr Soc. 2014; 73:470–476.